[Pulmonary infections with Mycobacterium xenopi in patients without HIV infection]

Rev Mal Respir. 2007 Mar;24(3 Pt 1):299-304. doi: 10.1016/s0761-8425(07)91061-x.
[Article in French]

Abstract

Objective: To determine the incidence, clinical characteristics, microbiological features and outcome of Mycobacterium xenopi infections in patients attending a university hospital.

Methods: We reviewed the files of HIV-seronegative patients meeting ATS criteria for M. xenopi pulmonary infection between 1993 and 2004.

Results: Ten patients were studied (7 men, 60+/-27 years). All but one had underlying chronic health disorders (chronic lung disease, cancer, alcoholism, systemic steroid therapy). The clinical and radiological findings were those associated with tuberculosis. Acid-fast bacilli were detected by direct examination in 9 cases, and antituberculous treatment prescribed in 8 patients. Specific treatment was started an average of 60+/-25 days after sampling, and generally combined a fluoroquinolone, clarithromycin and rifampicin, with or without ethambutol, for a mean of 11.4 months (1-37 months). Five patients had surgical excision (diagnostic in 1 case). Four patients died of their underlying disease. Two patients recovered with antibiotics alone and three with antibiotics and surgery. One patient was lost to follow-up after five months.

Conclusion: Pulmonary infection by M. xenopi is rare in HIV-seronegative patients. The prognosis depends mainly on the patient's underlying health status. Surgery is an important component of treatment.

Publication types

  • English Abstract

MeSH terms

  • Adult
  • Aged
  • Antitubercular Agents / therapeutic use
  • Female
  • Humans
  • Male
  • Middle Aged
  • Mycobacterium Infections, Nontuberculous / diagnosis*
  • Mycobacterium Infections, Nontuberculous / therapy
  • Mycobacterium xenopi / isolation & purification*
  • Retrospective Studies
  • Tuberculosis, Pulmonary / microbiology*
  • Tuberculosis, Pulmonary / therapy

Substances

  • Antitubercular Agents